Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

Trial StartSKB565Positive

AI Analysis

Summary

Kelun-Biotech received a clinical trial notice from China's Center for Drug Evaluation for SKB565, its first dual-payload antibody-drug conjugate, enabling advancement into clinical development.

Clinical Trial Data

Outcome Details

Clinical trial notice received from Center for Drug Evaluation (CDE)

Importance:5/10

Sentiment:

0.60

ADCdual-payloadclinical trialChinaCDE approval

Related Companies

$6990.HK

Read the original article

Published by PR Newswire Pharma on July 27, 2026 11:30 AM

Read Original